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Pemetrexed has been widely used in patients with advanced non-small cell lung cancer (NSCLC). The clinical relevance of polymorphisms
of folate pathway genes for pemetrexedmetabolism have not been fully elucidated yet. The aim of this study was to evaluate the expression
levels of circulating miR-22, miR-24, and miR-34a, possibly involved in folate pathway, in NSCLC patients treated with pemetrexed
compared with healthy controls and to investigate their impact on patient clinical outcomes. A total of 22 consecutive patients with
advanced NSCLC, treated with pemetrexed-based chemotherapy and 27 age and sex matched healthy controls were included in this
preliminary analysis. miR-22, miR-24, and miR-34a targets were identified by TargetScan 6.2 algorithm, validating the involvement of these
microRNAs in folate pathway. MicroRNAs were isolated from whole blood and extracted with miRNAeasy Mini Kit (Qiagen). miRNA
profiling was performed using Real-Time PCR. SPSS 17 was used to data analysis. miR-22, miR-24, and miR-34a were found upregulated
(P< 0.05) in NSCLC patients versus healthy controls. Higher expression levels were recorded for miR-34a. Nevertheless, significantly
higher miR-22 expression was observed in patients developing progressive disease (P¼ 0.03). No significant associations with clinical
outcome were recorded for miR-24 and miR-34a. Albeit preliminary, these data support the involvement of miR-22, miR-24, and miR-34a
in advanced NSCLC. The correlation between high expression of miR-22 in whole blood and the lack of response in pemetrexed treated
NSCLC patients indicates that miR-22 could represent a novel predictive biomarker for pemetrexed-based treatment.
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Despite significant improvements in the treatment of non-small
cell lung cancer (NSCLC) over the past several years, the
prognosis for patients with advanced disease remains poor.
Chemotherapy resistance is a key contributor to the dismal
prognoses for lung cancer patients.
However, important advances have been achieved in the
treatment of advanced NSCLC with the introduction of new
antiblastic and biological agents.
Lung cancer is driven by genomic alterations, and cancer
cells use multiple mechanisms to alter the activity of key genes:
mutation, amplification, deletion, intrachromosomal and
interchromosomal translocation, and epigenetic mechanisms
(MacConaill, 2012).
The progresses in the field of genomics during the past
decade have greatly advanced our understanding of the
genomic alterations that contribute to lung cancer, but
additional challenges must be addressed before the goal of
personalized cancer therapy can become a reality for lung
cancer patients.
Pemetrexed, a chemotherapeutic agent already approved in
the second-line setting (Hanna et al., 2004), has demonstrated
its efficacy also in the first-line treatment combined with
cisplatin (Scagliotti et al., 2008) and in the maintenance
treatment as single-agent in non-squamous NSCLC (Ciuleanu
et al., 2009; Paz-Ares et al., 2012), paving the way to the
so-called histotype-driven approach.
This multitargeted antifolate is unique among the folate
antagonists to inhibit at least three different enzymes in the
folate pathway: thymidylate synthase (TS), dihydrofolate
reductase (DHFR) and glycinamide ribonucleotide formyl
transferase (GARFT) (Gridelli et al., 2011).
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The clinical relevance of polymorphisms of folate pathway
genes for pemetrexed metabolism have not been fully
elucidated yet. Several genetic variations associated with folate
metabolic pathway and the downstream events have been
correlated with clinical outcome in patients treated with
pemetrexed (Kim et al., 2010; Franchina et al., 2011; Hou
et al., 2012; Tiseo et al., 2012).
The evolving novel world of microRNA offers an additional
regulatory layer affecting drug response. MicroRNAs
(miRNAs) are a group of small non-coding, single-stranded
RNAs of 22 nucleotides, that function as endogenous
negative gene regulators by binding to the 30-untranslated
region (UTR) of target mRNAs, repressing mRNA translation
or cleaving target mRNA (Lin et al., 2010). MiRNAs have been
implicated in a wide array of fundamental biological processes,
such as cell proliferation, differentiation, and apoptosis and
thus may function as oncogenes or tumor suppressing genes.
Accumulating evidence shows that miRNAs are grossly
dysregulated in human cancers, including NSCLC.
Importantly, circulating miRNAs have been characterized as
potential blood-based biomarkers for cancer detection. The
analysis of circulating miRNA profiles may improve not only
the knowledge of miRNA-mediated mechanisms, but may also
predict outcome for cancer patients (Gao et al., 2011).
However, the role of genetic alterations at miRNA loci
in the context of chemotherapy response has not been
extensively investigated.
MiRNAs have a key role in the modulation of folate-
mediated One-Carbon Metabolism (OCM) genes, that
comprises a set of reactions involving folate coenzymes, critical
for essential processes including DNA methylation, cell
proliferation, and the synthesis of nucleic and amino acids
(Stone et al., 2011). Preliminary studies suggest that folate
influences miRNA expression (Marsit et al., 2006).
Given these observations, we took a systematic approach to
identify which miRNAs could target critical enzymes in folate
pathway proteins and consequently influence response to
pemetrexed. Recent works have found that dihydrofolate
reductase, target enzymes of inhibition by pemetrexed, is
regulated at the translational level by miR-24 (Shookhoff and
Gallicano, 2010).
Further findings revealed that miR-22 and miR-34a target
methylenetetrahydrofolate reductase (MTHFR), key enzyme
in folate metabolism (Shookhoff and Gallicano, 2010; Stone
et al., 2011).
MTHFR polymorphisms have been associated with clinical
outcome in NSCLC patients treated with pemetrexed (Kim
et al., 2010; Franchina et al., 2011; Hou et al., 2012; Tiseo et al.,
2012).
Therefore, miR-22, mi-R24 and miR-34a might be potential
candidate biomarkers to predict pemetrexed response.
The aim of this study was to evaluate the expression levels of
circulating miR-22, miR-24, and miR-34a, possibly involved in
folate pathway, in NSCLC patients treated with pemetrexed
compared with healthy controls and to investigate their impact
on patient clinical outcomes.
Materials and Methods
A total of 22 consecutive patients with advanced NSCLC, before
starting treatment with pemetrexed-based chemotherapy and
27 age and sex matched healthy controls were included in this
preliminary analysis (Table 1). All cases had histological
confirmation of their tumor diagnosis.
All subjects were informed and gave written consent to
participate in the study to allow their biological samples to be
genetically analyzed, according to the Helsinki declaration.
We used the TargetScanS 6.2 algorithm (www.targetscan.org)
for genome-wide miRNA target prediction, validating the
involvement of miR-22, miR-24, and miR-34a in folate pathway and
possibly in pemetrexed metabolism.
For miRNA detection, whole blood samples (5ml per subject)
were collected via a direct venous puncture into tubes containing
EDTA, leaving the blood at room temperature for 1 h. Tubes were
then centrifuged at 3,000g for 10min at room temperature, and
the supernatant was aliquoted into Eppendorf tubes and stored
at 80˚C.
miRNAs extraction was performed with miRNeasy Mini Kit
(QIAGEN, Valencia, CA), designed for the purification of total
RNA, including miRNAs and other small molecules of RNA from
cultured cells and tissues. After the extraction a quantization was
carried out using the spectrophotometer NanoDrop ND-1000
(CelBio, Euroclone, Pero (Mi), Italy). The miRNAs were retro-
transcribed using TaqMan MicroRNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA). Conditions for the reverse
transcription reaction were as follows: 16˚C for 2min, 42˚C for
1min, 50˚C for 1 sec for 40 cycles, 85˚C for 5min then hold at 4˚C.
Obtained cDNAwas mixed with TaqManGene ExpressionMaster
Mix and loaded on a 96 multi-well plate.
Relative levels of gene expression were determined from
the fluorescence data generated during PCR using the ABI
PRISM7900HT Sequence Detection System. The data analysis was
conducted through the SDS software v.2.1. All experiments were
repeated at least three times. To normalize quantitative real-time
PCR reactions, parallel reactions were run on each sample for
RNU6B snRNA. Clinical and outcome data were collected.
RECIST criteria were used to evaluate tumor response to
pemetrexed.
Statistical analysis was performed using SPSS, version 17.0
(SPSS, Inc., Chicago, USA) for Windows. Intergroup group
comparisons were performed using analysis of variance (ANOVA).
Differences were considered statistically significant at P< 0.05.
Results and Discussion
The expression levels of miR-22, miR-24, and miR-34a were
profiled in the serum of 22 NSCLC patient samples, before
starting treatment with pemetrexed-based chemotherapy and
27 controls by qRT-PCR assay. The relative expression of
miRNAs was described as the difference in threshold cycle
number (Ct) between the samples and the controls.
As shown in Figure 1, the expression levels of miR-22, miR-
24, andmiR-34a were found significantly upregulated (P< 0.05)
in NSCLC patients versus healthy controls. Higher expression
levels were recorded for miR-34a.
Moreover, the levels of expression of miRNAs were
correlate to the response to pemetrexed-based chemotherapy.
miR-22 upregulation was reported in patients developing
progressive disease (P¼ 0.03). No significant associations with
clinical outcome were recorded for miR-24 and miR-34a.
TABLE 1. Demographic and clinical characteristics of patients
Characteristics Patients
Median age (range) 63 (46–78 years)
Sex (M/F) 14/8
Smokers 16
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Pemetrexed is extensively used in advanced non-squamous
lung cancer treatment, nevertheless few studies have
investigated genetic determinants of drug response and
resistance to this agent.
The potential role of miRNAs in pharmacogenomics is
currently an emerging avenue of investigation.
miRNAs are emerging as intriguing multi-protein target
regulators in the context of signaling networks involved in
cancer promotion or repression as well as biomarkers for
disease progression and response to treatment (Di Martino
et al., 2013).
In the era of tailored therapies, the noninvasive nature of
circulating miRNA collection and their sensitivity and
specificity encourage a pursuit of miRNA biomarker research.
Our preliminary data underline the central role of miRNAs
as a novel regulatory layer affecting drug metabolism and drug
targets, and thus should be taken into account when
conducting pharmacogenomic studies.
miR-22 upregulation in non-responder patients should
represent a novel predictive biomarker for treatment with
pemetrexed, but further investigations are needed to confirm
this preliminary observation.
Moreover, the upregulation of miR-22, miR-24, and miR-34a
in lung cancer patients could be represent a useful biomarker in
the follow up of early stage NSCLC and for innovative
approaches to early diagnosis in healthy heavy smokers.
Worldwide lung cancer research has focused on an ever-
increasing number of molecular elements of carcinogenesis at
genetic, epigenetic and protein levels. Proteomics analysis can
be a more reliable tool to discover novel cancer biomarkers,
particularly for lung cancer, for which, so far, DNA-based
biomarkers showed poor sensitivity, specificity, and
reproducibility (Indovina et al., 2013).
miRNAs are stably present in sputum of cancer patients and
therefore, they represent the main candidates as biomarkers
(D’Urso et al., 2013).
To the best of our knowledge this is the first study reporting
a similar correlation and suggesting a possible implication of
genetic variations associatedwith folate metabolic pathway and
the downstream events with clinical outcome in NSCLC
patients treated with pemetrexed.
Further validations and investigations will be needed to
define the role of these miRNAs as useful biomarkers in
pemetrexed treated NSCLC patients and evaluate their
correlations with genotypes of folate metabolizing enzymes.
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Fig. 1. Expression levels of miR-22, miR-24, and miR-34a.
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